Research progress on treatment of medication-related osteonecrosis of the jaw

doi:10.19438/j.cjoms.2020.05.017

Abstract

Abstract: Medication-related osteonecrosis of the jaw is a complication in patients taking antiresorptive or antiangiogenic drugs. It destroys oral hygiene, affects patients' eating, speech and reduces their quality of life. There is no consensus on the most appropriate treatment strategy for medication-related osteonecrosis of the jaw till now. This article summarized the recent research on staging and adjuvant treatment of medication-related osteonecrosis of the jaw.

Key words: Medication-related osteonecrosis of the jaw, Bisphosphonate, Staging, Therapy

CLC Number:

R782.3

JIANG Jun-jian, HE Yue. Research progress on treatment of medication-related osteonecrosis of the jaw[J]. China Journal of Oral and Maxillofacial Surgery, 2020, 18(5): 474-477.

References

[1] Stevenson M, Jones ML, De Nigris E, et al.A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis[J]. Health Technol Assess, 2005, 9(22): 1-160.
[2] Marx RE.Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic[J]. J Oral Maxillofac Surg, 2003, 61(9): 1115-1157.
[3] Greuter S, Schmid F, Ruhstaller T, et al.Bevacizumab-associated osteonecrosis of the jaw[J]. Ann Oncol, 2008, 19(12): 2091-2092.
[4] Koch FP, Walter C, Hansen T, et al.Osteonecrosis of the jaw related to sunitinib[J]. Oral Maxillofac Surg, 2011, 15(1): 63-66.
[5] Owosho AA, Scordo M, Yom SHK, et al.Osteonecrosis of the jaw a new complication related to Ipilimumab[J]. Oral Oncol, 2015, 51(12): e100-101.
[6] Ruggiero SL, Dodson TB, Fantasia J, et al.American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update[J]. J Oral Maxillofac Surg, 2014, 72(10): 1938-1956.
[7] Allen BW, Demchenko IT, Piantadosi CA.Two faces of nitric oxide: implications for cellular mechanisms of oxygen toxicity[J]. J Appl Physiol(1985), 2009, 106(2): 662-667.
[8] Piantadosi CA, Tatro LG.Regional H₂O₂ concentration in rat brain after hyperoxic convulsions[J]. J Appl Physiol(1985), 1990, 69(5): 1761-1766.
[9] Demchenko IT, Boso AE, O'Neill TJ, et al. Nitric oxide and cerebral blood flow responses to hyperbaric oxygen[J]. J Appl Physiol(1985), 2000, 88(4): 1381-1389.
[10] Demchenko IT, Boso AE, Whorton AR, et al.Nitric oxide production is enhanced in rat brain before oxygen-induced convulsions[J]. Brain Res, 2001, 917(2): 253-261.
[11] Boykin Jr JV, Baylis C.Hyperbaric oxygen therapy mediates increased nitric oxide production associated with wound healing: a preliminary study[J]. Adv Skin Wound Care, 2007, 20(7): 382-388.
[12] Freiberger JJ.Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws[J]. J Oral Maxillofac Surg, 2009, 67(5 Suppl): 96-106.
[13] Freiberger JJ, Padilla-Burgos R, McGraw T, et al. What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics[J]. J Oral Maxillofac Surg, 2012, 70(7): 1573-1583.
[14] Delanian S.Striking regression of radiation-induced fibrosis by a combination of pentoxifylline and tocopherol[J]. Br J Radiol, 1998, 71(848): 892-894.
[15] Delanian S, Depondt J, Lefaix JL.Major healing of refractory mandible osteoradionecrosis after treatment combining pentoxifylline and tocopherol: a phase Ⅱ trial[J]. Head Neck, 2005, 27(2): 114-123.
[16] Delanian S, Porcher R, Rudant J, et al.Kinetics of response to long-term treatment combining pentoxifylline and tocopherol in patients with superficial radiation-induced fibrosis[J]. J Clin Oncol, 2005, 23(34): 8570-8579.
[17] Epstein MS, Wicknick FW, Epstein JB, et al.Management of bisphosphonate-associated osteonecrosis: pentoxifylline and tocopherol in addition to antimicrobial therapy. An initial case series[J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2010, 110(5): 593-596.
[18] Magremanne M, Reychler H.Pentoxifylline and tocopherol in the treatment of yearly zoledronic acid-related osteonecrosis of the jaw in a corticosteroid-induced osteoporosis[J]. J Oral Maxillofac Surg, 2014, 72(2): 334-337.
[19] Owosho AA, Estilo CL, Huryn JM, et al.Pentoxifylline and tocopherol in the management of cancer patients with medication-related osteonecrosis of the jaw: an observational retrospective study of initial case series[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2016, 122(4): 455-459.
[20] Ripamonti CI, Cislaghi E, Mariani L, et al.Efficacy and safety of medical ozone (O₃) delivered in oil suspension applications for the treatment of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: preliminary results of a phase Ⅰ-Ⅱstudy[J]. Oral Oncol, 2011, 47(3): 185-190.
[21] Agrillo A, Filiaci F, Ramieri V, et al.Bisphosphonate-related osteonecrosis of the jaw (BRONJ): 5 year experience in the treatment of 131 cases with ozone therapy[J]. Eur Rev Med Pharmacol Sci, 2012, 16(12): 1741-1747.
[22] Cheung A, Seeman E.Teriparatide therapy for alendronate-associated osteonecrosis of the jaw[J]. N Engl J Med, 2010, 363(25): 2473-2474.
[23] Dayisoylu EH, Senel FÇ, Üngör C, et al.The effects of adjunctive parathyroid hormone injection on bisphosphonate-related osteonecrosis of the jaws: an animal study[J]. Int J Oral Maxillofac Surg, 2013, 42(11): 1475-1480.
[24] Kim KM, Park W, Oh SY, et al.Distinctive role of 6-month teriparatide treatment on intractable bisphosphonate-related osteonecrosis of the jaw[J]. Osteoporos Int, 2014, 25(5): 1625-1632.
[25] Kakehashi H, Ando T, Minamizato T, et al.Administration of teriparatide improves the symptoms of advanced bisphosphonate-related osteonecrosis of the jaw: preliminary findings[J]. Int J Oral Maxillofac Surg, 2015, 44(12): 1558-1564.
[26] Badran Z, Abdallah MN, Torres J, et al.Platelet concentrates for bone regeneration: Current evidence and future challenges[J]. Platelets, 2018, 29(2): 105-112.
[27] Tsai LL, Huang YF, Chang YC.Treatment of bisphosphonate-related osteonecrosis of the jaw with platelet-rich fibrin[J]. J Formos Med Assoc, 2016, 115(7): 585-586.
[28] Adornato MC, Morcos I, Rozanski J.The treatment of bisphosphonate-associated osteonecrosis of the jaws with bone resection and autologous platelet-derived growth factors[J]. J Am Dent Assoc, 2007, 138(7): 971-977.
[29] Curi MM, Cossolin GSI, Koga DH, et al.Bisphosphonate-related osteonecrosis of the jaws-an initial case series report of treatment combining partial bone resection and autologous platelet-rich plasma[J]. J Oral Maxillofac Surg, 2011, 69(9): 2465-2472.
[30] Fernando de Almeida Barros Mourão C, Calasans-Maia MD, Del Fabbro M, et al. The use of Platelet-rich fibrin in the management of medication-related osteonecrosis of the jaw: a case series[J]. J Stomatol Oral Maxillofac Surg, 2020, 121(1):84-89.
[31] Giudice A, Barone S, Giudice C, et al.Can platelet-rich fibrin improve healing after surgical treatment of medication-related osteonecrosis of the jaw? A pilot study[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2018, 126(5): 390-403.
[32] Nφrholt SE, Hartlev J.Surgical treatment of osteonecrosis of the jaw with the use of platelet-rich fibrin: a prospective study of 15 patients[J]. Int J Oral Maxillofac Surg, 2016, 45(10): 1256-1260.